期刊文献+

肿瘤标志物CYFRA21-1、SCC、CEA、NSE、CA125检验在肺癌诊断中的价值 被引量:45

Diagnostic value of tumor markers CYFRA21-1,SCC,CEA,NSEand CA125 in lung cancer
下载PDF
导出
摘要 目的:分析肿瘤标志物细胞角蛋白19片段(CYFRA21-1)、鳞状上皮细胞癌抗原(SCC)、癌胚抗原(CEA)、神经特异性烯醇化酶(NSE)以及糖类癌抗原125(CA125)检验在肺癌诊断中的临床应用价值。方法:将2015年11月至2016年11月于我院收治的74例肺癌患者(肺癌组)、74例肺良性肿瘤患者(良性肿瘤组)作为研究对象,同期选择74例到院体检的健康人群作为健康组。三组患者均在空腹状态下抽取4.0 ml静脉血,离心处理后进行实验室检验。对比三组患者中CYFRA21-1、SCC、CEA、NSE以及CA125水平的变化情况。结果:肺癌组的CYFRA21-1、SCC、CEA、NSE以及CA125水平均高于健康组和良性肿瘤组(P<0.05)。非小细胞肺癌患者的CYFRA21-1、SCC、CEA以及CA125水平均高于小细胞肺癌患者。小细胞肺癌患者的NSE水平显著高于非小细胞肺癌患者(P<0.05)。结论:肺癌患者的CYFRA21-1、SCC、CEA、NSE以及CA125水平将会显著增高,通过联合检测CYFRA21-1、SCC、CEA、NSE以及CA125能够在一定程度上提高肺癌疾病的诊断准确率,对于肺癌疾病的临床诊断和筛查具有十分重要的作用。 Objective:To analyze the clinical value of tumor markers cytokeratin 19 fragment( CYFRA21-1),squamous cell carcinoma antigen( SCC),carcinoembryonic antigen( CEA),neuron specific enolase( NSE) and carbohydrate antigen 125( CA125) in the diagnosis of lung cancer.Methods:There were 74 cases of patients with lung cancer from November 2015 to November 2016 in our hospital( lung cancer group),74 cases of lung benign tumor patients( benign group) as the research object,and 74 cases of healthy people to the hospital as a health group.In the fasting state,4.0 ml venous blood was extracted in three groups of patients,after centrifugation laboratory test was did.The three groups of tumor marker levels in CYFRA21-1,SCC,CEA,NSE and CA125 were compared.Results:The levels of CYFRA21-1,SCC,CEA,NSE and CA125 in lung cancer group were significantly higher than those in healthy group and benign tumor group( P〈0.05).The levels of CYFRA21-1,SCC,CEA and CA125 in patients with non-small cell lung cancer were higher than those in patients with small cell lung cancer.The level of NSE in patients with small cell lung cancer was significantly higher than that in patients with non-small cell lung cancer( P〈0.05).Conclusion:CYFRA21-1,SCC,CEA,NSE and CA125 levels in lung cancer patients will be significantly increased.Combined detection of CYFRA21-1,SCC,CEA,NSE and CA125 to diagnose lung cancer in a certain extent,could improve the accuracy,which plays an important role in clinical diagnosis and screening of lung cancer.
作者 张颖 董秀鹏 杜静 刘敏 王金文 Zhang Ying;Dong Xiupeng;Du Jing;Liu Min;Wang Jinwen(Department of Clinical Laboratory,Daqing Oilfield General Hospital,Heilongjiang Daqing 163453,China.)
出处 《现代肿瘤医学》 CAS 2018年第11期1701-1703,共3页 Journal of Modern Oncology
基金 大庆市科学技术进步奖(编号:2014-052-07)
关键词 肺癌 肿瘤标志物 检验 诊断价值 lung cancer tumor marker examination diagnostic value
  • 相关文献

参考文献3

二级参考文献51

  • 1Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353: 123-32.
  • 2Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated (INTEREST): a randomized phase Ⅲ trial. Lancet 2008, 372: 1809-18.
  • 3Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyro-sine kinase, in symptomatic patients with non-small cell lun cancer: a randomized trial. JAMA 2003, 290: 2149-58.
  • 4Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Onco12003, 21: 2237-46.
  • 5Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366: 1527-37.
  • 6Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Onco12010, 11:121-8.
  • 7Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Onco12009, 27: 1394-400.
  • 8Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361: 947-57.
  • 9Li C, Fang R, Sun Y, Han X, Li F, Gao B, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 2011, 6: e28204.
  • 10Trape J, Buxo J, Perez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003, 23: 4277-81.

共引文献115

同被引文献375

引证文献45

二级引证文献267

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部